Center for Vaccinology, University Hospitals of Geneva, Geneva, Switzerland.
Departments of Pathology-Immunology and Pediatrics, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Pediatr Allergy Immunol. 2021 Jan;32(1):9-16. doi: 10.1111/pai.13401. Epub 2020 Nov 20.
Tremendous efforts are undertaken to quickly develop COVID-19 vaccines that protect vulnerable individuals from severe disease and thereby limit the health and socioeconomic impacts of the pandemic. Potential candidates are tested in adult populations, and questions arise of whether COVID-19 vaccination should be implemented in children. Compared to adults, the incidence and disease severity of COVID-19 are low in children, and despite their infectiveness, their role in disease propagation is limited. Therefore, COVID-19 vaccines will need to have fully demonstrated safety and efficacy in preventing not only complications but transmission to justify childhood vaccination. This work summarizes currently tested vaccine platforms and debates practical and ethical considerations for their potential use in children. It also discusses the already deleterious effect of the pandemic on routine childhood vaccine coverage, calling for action to limit the risks for a rise in vaccine-preventable diseases.
人们正在全力以赴地开发 COVID-19 疫苗,以保护弱势群体免受重症疾病的侵害,从而限制大流行对健康和社会经济的影响。潜在的候选疫苗在成年人群体中进行测试,由此产生了 COVID-19 疫苗是否应在儿童中接种的问题。与成年人相比,儿童 COVID-19 的发病率和疾病严重程度较低,尽管他们具有传染性,但他们在疾病传播中的作用有限。因此,COVID-19 疫苗需要充分证明其在预防不仅是并发症,而且是传播方面的安全性和有效性,以证明儿童接种疫苗的合理性。这项工作总结了目前测试的疫苗平台,并对其在儿童中的潜在使用进行了实际和伦理方面的考虑。它还讨论了大流行对常规儿童疫苗接种覆盖率已经产生的有害影响,呼吁采取行动限制疫苗可预防疾病上升的风险。